ymav4294, thanks for your posts!
Some meaningful info in the sea of surprised why posts.
"Oops, PRR did it again".
In regards to the CVAC2018 and CVAC1012 patients I believe one of them had progressed "prior to receipt of Cvac" (Abstract results). I reckon it does not really matter for the stats output, but matters to the CVac efficiency.
I still need to digest and review the results with a clear head, but I think it's too early to say that CVac is better for the patients in the 2nd remissions. The results show that the patients stay NED longer in the 1st remission (either Cvac or OSC (compare to the results for the 2nd remissions). In other words more time is required to observe the group in the 1st remission.
interim data from can-003 clinical trial, page-13
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $465.4M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 31.8¢ | $845.3K | 2.621M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 140318 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 14222 | 1 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |